Current guidelines poorly address multimorbidity: Pilot of the interaction matrix method

Christiane Muth, Hanna Kirchner, Marjan Van Den Akker, Martin Scherer, Paul P. Glasziou

Research output: Contribution to journalArticleResearchpeer-review

21 Citations (Scopus)

Abstract

Objectives To develop a framework to identify and classify interactions within and among treatments and conditions and to test this framework with guidelines on chronic heart failure (CHF) and its frequent comorbidity.

Study Design and Setting Text analysis of evidence-based clinical practice guidelines on CHF and 18 conditions co-occurring in ≥5% of CHF patients (2-4 guidelines per disease). We extracted data on interactions between CHF and comorbidity and key recommendations on diagnostic and therapeutic management. From a subset of data, we derived 13 subcategories within disease-disease (Di-Di-I), disease-drug (Di-D-I), drug-drug interactions (DDI) and synergistic treatments. We classified the interactions and tested the interrater reliability, refined the framework, and agreed on the matrix of interactions.

Results We included 48 guidelines; two-thirds provided information about comorbidity. In total, we identified N = 247 interactions (on average, 14 per comorbidity): 68 were Di-Di-I, 115 were Di-D-I, 12 were DDI, and 52 were synergisms. All 18 comorbidities contributed at least one interaction.

Conclusion The interaction matrix provides a structure to present different types of interactions between an index disease and comorbidity. Guideline developers may consider the matrix to support clinical decision making in multimorbidity. Further research is needed to show its relevance to improve guidelines and health outcomes.

Original languageEnglish
Pages (from-to)1242-1250
Number of pages9
JournalJournal of Clinical Epidemiology
Volume67
Issue number11
DOIs
Publication statusPublished - 1 Nov 2014

Fingerprint

Comorbidity
Guidelines
Heart Failure
Drug Interactions
Pharmaceutical Preparations
Evidence-Based Practice
Practice Guidelines
Therapeutics
Health
Research

Cite this

Muth, Christiane ; Kirchner, Hanna ; Van Den Akker, Marjan ; Scherer, Martin ; Glasziou, Paul P. / Current guidelines poorly address multimorbidity : Pilot of the interaction matrix method. In: Journal of Clinical Epidemiology. 2014 ; Vol. 67, No. 11. pp. 1242-1250.
@article{67f73fa8c64746cbb6f14c33998ad3fb,
title = "Current guidelines poorly address multimorbidity: Pilot of the interaction matrix method",
abstract = "Objectives To develop a framework to identify and classify interactions within and among treatments and conditions and to test this framework with guidelines on chronic heart failure (CHF) and its frequent comorbidity.Study Design and Setting Text analysis of evidence-based clinical practice guidelines on CHF and 18 conditions co-occurring in ≥5{\%} of CHF patients (2-4 guidelines per disease). We extracted data on interactions between CHF and comorbidity and key recommendations on diagnostic and therapeutic management. From a subset of data, we derived 13 subcategories within disease-disease (Di-Di-I), disease-drug (Di-D-I), drug-drug interactions (DDI) and synergistic treatments. We classified the interactions and tested the interrater reliability, refined the framework, and agreed on the matrix of interactions.Results We included 48 guidelines; two-thirds provided information about comorbidity. In total, we identified N = 247 interactions (on average, 14 per comorbidity): 68 were Di-Di-I, 115 were Di-D-I, 12 were DDI, and 52 were synergisms. All 18 comorbidities contributed at least one interaction.Conclusion The interaction matrix provides a structure to present different types of interactions between an index disease and comorbidity. Guideline developers may consider the matrix to support clinical decision making in multimorbidity. Further research is needed to show its relevance to improve guidelines and health outcomes.",
author = "Christiane Muth and Hanna Kirchner and {Van Den Akker}, Marjan and Martin Scherer and Glasziou, {Paul P.}",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.jclinepi.2014.07.004",
language = "English",
volume = "67",
pages = "1242--1250",
journal = "Journal of Chronic Diseases",
issn = "0895-4356",
publisher = "Elsevier",
number = "11",

}

Current guidelines poorly address multimorbidity : Pilot of the interaction matrix method. / Muth, Christiane; Kirchner, Hanna; Van Den Akker, Marjan; Scherer, Martin; Glasziou, Paul P.

In: Journal of Clinical Epidemiology, Vol. 67, No. 11, 01.11.2014, p. 1242-1250.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Current guidelines poorly address multimorbidity

T2 - Pilot of the interaction matrix method

AU - Muth, Christiane

AU - Kirchner, Hanna

AU - Van Den Akker, Marjan

AU - Scherer, Martin

AU - Glasziou, Paul P.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Objectives To develop a framework to identify and classify interactions within and among treatments and conditions and to test this framework with guidelines on chronic heart failure (CHF) and its frequent comorbidity.Study Design and Setting Text analysis of evidence-based clinical practice guidelines on CHF and 18 conditions co-occurring in ≥5% of CHF patients (2-4 guidelines per disease). We extracted data on interactions between CHF and comorbidity and key recommendations on diagnostic and therapeutic management. From a subset of data, we derived 13 subcategories within disease-disease (Di-Di-I), disease-drug (Di-D-I), drug-drug interactions (DDI) and synergistic treatments. We classified the interactions and tested the interrater reliability, refined the framework, and agreed on the matrix of interactions.Results We included 48 guidelines; two-thirds provided information about comorbidity. In total, we identified N = 247 interactions (on average, 14 per comorbidity): 68 were Di-Di-I, 115 were Di-D-I, 12 were DDI, and 52 were synergisms. All 18 comorbidities contributed at least one interaction.Conclusion The interaction matrix provides a structure to present different types of interactions between an index disease and comorbidity. Guideline developers may consider the matrix to support clinical decision making in multimorbidity. Further research is needed to show its relevance to improve guidelines and health outcomes.

AB - Objectives To develop a framework to identify and classify interactions within and among treatments and conditions and to test this framework with guidelines on chronic heart failure (CHF) and its frequent comorbidity.Study Design and Setting Text analysis of evidence-based clinical practice guidelines on CHF and 18 conditions co-occurring in ≥5% of CHF patients (2-4 guidelines per disease). We extracted data on interactions between CHF and comorbidity and key recommendations on diagnostic and therapeutic management. From a subset of data, we derived 13 subcategories within disease-disease (Di-Di-I), disease-drug (Di-D-I), drug-drug interactions (DDI) and synergistic treatments. We classified the interactions and tested the interrater reliability, refined the framework, and agreed on the matrix of interactions.Results We included 48 guidelines; two-thirds provided information about comorbidity. In total, we identified N = 247 interactions (on average, 14 per comorbidity): 68 were Di-Di-I, 115 were Di-D-I, 12 were DDI, and 52 were synergisms. All 18 comorbidities contributed at least one interaction.Conclusion The interaction matrix provides a structure to present different types of interactions between an index disease and comorbidity. Guideline developers may consider the matrix to support clinical decision making in multimorbidity. Further research is needed to show its relevance to improve guidelines and health outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84908248517&partnerID=8YFLogxK

U2 - 10.1016/j.jclinepi.2014.07.004

DO - 10.1016/j.jclinepi.2014.07.004

M3 - Article

VL - 67

SP - 1242

EP - 1250

JO - Journal of Chronic Diseases

JF - Journal of Chronic Diseases

SN - 0895-4356

IS - 11

ER -